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The differential diagnosis between Burkitt lymphoma (BL) and diffuse large B-cell 
lymphoma (DLBCL) can be challenging. BL has been reported to express less 
BCL2 than DLBCL, but this issue has not been analyzed systematically. BL ex-
pressing BCL2 can be considered to be MYC/BCL2 co-expressors, a feature that 
is associated with poorer outcome in DLBCL but that has not been correlated 
with outcome in BL so far. We analyzed the expression of BCL2 in 150 cases of 
conventionally diagnosed BL using two different BCL2 antibodies. BCL2 expres-
sion was detected in 22% of the cases, though the expression varied in intensity 
and number of positive cells. Using a subgroup of 43 cases for which detailed 
clinical data were available, we did not detect any relevant differences in clinical 
presentation and outcome between BCL2-positive and BCL2-negative BL. An 
independent cohort of 17 BL with expression of BCL2 were analyzed molecularly 
with 13 of 17 cases classified as molecularly defined BL using gene expression 
profiling on formalin-fixed paraffin-embedded tissues. The four lymphomas di-
agnosed molecularly as intermediates did not differ in clinical presentation and 
outcome from molecularly defined BL. 
intRoDuCtion
The differential diagnosis of Burkitt lymphoma (BL) versus diffuse large B-cell lym-
phoma (DLBCL) can be challenging. In daily practice their diagnosis is based on 
morphological assessment, immunophenotype and detection of translocations of 
the MYC and absence of translocations involving the BCL2 or BCL6 gene by fluo-
rescence in situ hybridization (FISH) (conventionally diagnosed BL). The immuno-
phenotype, which is assessed to distinguish BL from DLBCL, frequently includes 
BCL2 expression (Cogliatti et al, 2006;Salaverria & Siebert, 2011;Kluin & Schuur-
ing, 2011). The former WHO classification published in 2001 stated that BCL2 is 
not expressed in BL (Jaffe et al, 2001). However, gene expression profiling iden-
tified cases of molecularly defined BL (mBL) with BCL2 expression not caused by 
translocations of the gene (Hummel et al, 2006;Dave et al, 2006). These findings 
led to a new weighting of the immunophenotypic features of BL in the current 
WHO classification, which describes BCL2 as being expressed in up to 20% of 
BL cases, predominantly with a weak expression pattern (Swerdlow et al, 2008). 
BL expressing BCL2 must be distinguished from the group of lymphomas called 
“B-cell lymphomas unclassified with features intermediate between BL and DLB-
CL” (conventionally diagnosed intermediates), which comprises a heterogeneous 
group of lymphomas. Conventionally diagnosed intermediate lymphomas show 
at least some features reminiscent of BL, such as a monomorphic cytological 
picture with small to medium-sized blasts, a starry sky pattern, high proliferation 
and frequently translocations involving the MYC gene (Swerdlow et al, 2008). 
However, conventionally diagnosed intermediate lymphomas often display im-
munophenotypic features such as strong BCL2 expression or genetic features 
like BCL2 or BCL6 gene translocations that preclude a BL diagnosis. The pres-
ence of both MYC and BCL2 or BCL6 translocations is called “double hit” and is 
usually not compatible with the diagnosis of BL (Aukema et al, 2011;Aukema et 
al, 2014;Boerma et al, 2009). 
Intermediate lymphomas can also be identified by gene expression profiling in-
dependent of morphology, immunophenotype and FISH data. Gene expression 
profiling-based molecular intermediates (m-intermediates) are classified as con-
ventionally diagnosed BL or DLBCL by conventional diagnostics. A subgroup of 
m-intermediates lack a genetic “double hit” constellation (Hummel et al, 2006). 
In children and adolescents translocations of BCL6 and BCL2, and thus “dou-
ble hit” lymphomas, are exceedingly rare, but m-intermediates in the young age 
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group can be detected by gene expression profiling (Klapper et al, 2008). Similar 
to “double hit” lymphomas, m-intermediates identified by gene expression pro-
filing occasionally express BCL2 protein (Klapper et al, 2008). Currently, gene 
expression profiling is not available for a routine diagnosis, thus for diagnostic 
pathologists it is currently unclear whether strong expression of BCL2 justifies the 
classification of a case with the morphological and immunophenotypical features 
of a BL as an intermediate lymphoma.
In DLBCL not only the genetic “double hit” with MYC and BCL2 translocations but 
also the co-expression of both proteins MYC and BCL2 (“co-expressor”) charac-
terize a subgroup of DLBCL with an aggressive course (Horn et al, 2013;Green 
et al, 2012;Perry et al, 2014;Hu et al, 2013;Johnson et al, 2009). In BL, high lev-
els of MYC protein expression is due to the MYC translocations (Hummel et al, 
2006). Whether the co-expression with BCL2 indicates inferior poorer outcome in 
BL has not yet been studied.
To gain a better understanding of the clinical implications, we systematically an-
alyzed BCL2 expression in BL. To this end we screened a large cohort of con-
ventionally diagnosed BL for BCL2 expression using two antibodies that detect 
BCL2. We correlated the BCL2 expression status with the clinical course in cases 
with available clinical data. Moreover, we applied digital multiplexed gene expres-
sion profiling on formalin-fixed paraffin-embedded (FFPE) tissue specimens from 
BCL2-positive BCL2-negative conventionally diagnosed BL cases to determine 
whether they are classified as mBL. 
PAtients AnD MethoDs
Patients and tissue specimens
BL cases from all age groups that were diagnosed between 2001 and 2014 were 
identified within the files of the Lymph Node Registry Kiel. Cases with sufficient 
FFPE tissue were arranged in a tissue microarray (TMA) with duplicate cores 0.6 
mm in diameter for each lymphoma. We included only lymphomas with morpho-
logical features compatible with the diagnosis of conventionally diagnosed BL as 
judged on full tissue sections. The lymphomas were composed of dense sheets 
of monomorphic small to medium-sized blasts with a narrow rim of cytoplasm 
showing cohesive growth and a starry sky pattern in areas of good tissue pres-
ervation. The TMA cohort comprised a total of 150 cases of conventionally diag-
nosed BL from all age groups. A subgroup of cases with specimens of sufficient 
size and a tumor content of at least 70% were selected for molecular analysis 
(n=17). Clinical data were available for 43 cases.
Immunohistochemistry and fluorescence in situ hybridization (FISH)
Analysis of BCL2 expression was conducted using clone 100/D5 (DAKO, 
Glostrup, Denmark) or clone E17 (Zytomed, Berlin, Germany)(Adam et al, 2013). 
Analysis of CD20, CD10 and Ki67 was performed using an automated stainer 
(Leica, Wetzlar, Germany). BCL2 immunohistochemistry results were scored by 
visual inspection in the following categories: negative (no staining in lympho-
ma cells), 1-25% positive lymphoma cells, 26-50% positive lymphoma cells, 51-
75% positive lymphoma cells and >75% positive lymphoma cells. The intensity 
of BCL2 staining was analyzed relative to non-neoplastic T-cells serving as an 
internal control as weak (weaker than T-cells) or strong (stronger or equal to 
T-cells). Staining intensity of T-cells also served as a control for immunoreactivity 
of the tissue.The Ki67 index was assessed in 5% steps, whereas CD20, CD10 
and TdT were reported as positive or negative. FISH was conducted as described 
recently(Ventura et al, 2006). Break-apart probes for the MYC , BCL2and BCL6 
loci as well as IGH-MYC and IGH-BCL2 fusion probes were applied (Abbott, Ab-
bott Park, Illinois, USA) (Barth et al, 2013).
RnA extraction and digital multiplexed gene expression
FFPE material was cut into five 10 µm-thick sections per sample. Extraction of 
RNA was done according to the manufacturer’s instructions (ExpressArt FFPE 
Clear RNAready Kit, AmpTec, Hamburg, Germany), quantified and checked for 
quality (Agilent RNA 6000 Nano Chips, Agilent Technologies, Santa Clara, Califor-
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nia, USA) as previously described (Masque-Soler et al, 2013). Gene expression 
analysis was performed using nCounter/Nanostring technology following the pre-
viously published protocol (Masque-Soler et al, 2013). In five specimens with pre-
viously visualized BCL2 expression pattern on FFPE sections, BCL2-positive and 
-negative areas were analogously labeled on unstained tissue sections, manually 
dissected and separately processed for RNA extraction and gene expression.
Results
incidence of BCl2 expression in conventionally diagnosed Bl
We analyzed 150 cases of conventionally diagnosed BL diagnosed by morpho-
logical and immunophenotypical features as well as the presence of MYC trans-
locations. All cases were positive for CD20, CD10 and negative for TdT with a 
Ki67 index above 90%. All lymphomas were shown by fluorescence in situ hybrid-
ization to harbor MYC (150/150, 100%) translocations but to lack BCL2 (0/141, 
0%) or BCL6 (0/137, 0%) translocations. TMAs containing our case cohort were 
stained by two antibodies directed against BCL2. Applying the most widely used 
antibody clone 100/D5, 146 cases yielded an interpretable result. No expression 
was detected in 113/146 cases (77%). BCL2 expression was detected at various 
levels in 33/146 (23%) of the cases with interpretable results (1-25% positive lym-
phoma cells in 16/150 (11%), 26-50% in 6/150 (4%), 51-75% in 6/150 (4%) and 
>75% in 5/50 (3%)). The expression intensity was weak (weaker than non-neo-
plastic T-cells as internal controls) in the majority of cases (figure 1) and only two 
cases showed strong staining intensity equal to or stronger than nonneoplastic 
T-cells (data not shown). To analyze whether BCL2 protein expression might es-
cape detection by the frequently used antibody clone 100/D5, as reported for 
follicular lymphoma (Adam et al, 2013), the cases were additionally analyzed by 
the antibody clone E17. However, none of the conventionally diagnosed BL that 
lacked BCL2 expression using the clone 100/D5 stained positive with the clone 
E17 (0/104 of cases with interpretable results, supplementary table 2). 
figure 1 | Variable expression of BCL2 in BL. Scattered cells comprising about 10% of all 
lymphoma cells (A, corresponding to case 9 in table 1) and diffusely dispersed BCL2-posi-
tive lymphoma cells comprising about 40% (B, corresponding to case 12 in table 1). Insets 
with high magnifications with arrowheads indicating nonneoplastic T-cells and arrows indi-
cating BCL2-positive lymphoma cells.
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Pathological features of conventionally diagnosed Bl showing expression 
of BCl2
A subgroup of 17 patients with conventionally diagnosed BL was further studied 
on full tissue sections (7 of these patients wera also part of the TMA cohort). 
The patients’ clinical features were typical for BL and they were predominantly 
young (median age 11 years, range 3-24 years) and male (table 1). All but one 
patient presented with lymphomas with no or limited bone marrow infiltration and 
they were frequently at a limited stage (table 1). The lymphomas manifested pre-
dominantly at extranodal sites with 10/17 in the small or large intestine or as an 
abdominal or ileocecal mass (table 1). 
Histopathology and genetics were compatible with the diagnosis of conventionally 
diagnosed BL, with small to medium-sized blasts with a narrow rim of cytoplasm. 
A starry sky pattern was detectable in the majority of cases, at least in areas with 
good tissue preservation. A plasmacytic differentiation was not detectable. All lym-
phomas displayed the conventionally diagnosed BL immunophenotype with ex-
pression of CD20 and CD10, high proliferation as measured by the Ki67 index and 
absence of TdT expression (table 1). Only 1/8 cases (13%) was positive for EBV by 
EBER in situ hybridization (data not shown). The genetic features were compatible 
with the diagnosis conventionally diagnosed BL too (table 1). The BCL2-expressing 
cells were either diffusely dispersed over the whole lymphoma/tumor or clustered in 
restricted areas while leaving other areas BCL2-negative (figure 2). In cases with 
spatially divergent BCL2 expression, the phenotype and the morphology did not 
differ between BCL2-positive and BCL2-negative areas of the lymphoma (figure 
2). Spatially divergent BCL2 expression occurred in 23% of the cases analyzed.
BCL2-positive conventionally diagnosed BL show a molecular profile of 
mBl or m-intermediate
In order to understand whether the expression of BCL2 in conventionally diag-
nosed BL truly is a BL, we performed a gene expression analysis using RNA 
obtained from FFPE tissues and digital multiplexed gene expression technology, 
as previously published (Masque-Soler et al, 2013). Thirteen of 17 convention-
ally diagnosed BL (76%) were classified as mBL, confirming the clinicopatho-
logical-cytogenetic diagnosis (table 1). In five specimens the BCL2-positive and 
negative areas of the conventionally diagnosed BL were manually dissected and 
analyzed separately for gene expression. All of these were classified as mBL in 
both the BCL2-negative and the BCL2-positive areas of the tumor (case 1, 2, 3, 
4 and 11 in table 1).
figure 2 | Example of a case of BL with differential spatial expression of BCL2. The spec-
imen was obtained from an ileocecal mass in a 12-year-old male child (case number 1 in 
table 1). The tumor displays heterogeneous expression of BCL2 (A, overview; B and C 
high magnification). Both areas with and without BCL2 expression show the typical mor-
phology and immunophenotype of BL. BCL2-positive areas: B, BCL2, D, hematoxylin and 
eosin, F, CD20, G, CD10, H, Ki67. BCL2-negative areas: C, BCL2, E, hematoxylin and 
eosin, I, CD20, J, CD10, K, Ki67. 
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Interestingly, 4/17 conventionally diagnosed BL (24%) were classified as lympho-
mas intermediate between mBL and non-mBL (m-intermediate, case 5, 6, 13 and 
16 in table 1, Figure 3). All m-intermediate lymphomas showed typical features 
of conventionally diagnosed BL. The patients were under the age of 16 and 3 
patients presented with an abdominal mass (table 1). Although the morphology 
of these lymphomas was ambiguous due to poor tissue quality (Figure 3), all lym-
phomas were positive for t(8;14) and lacked BCL6 breaks. There were no BCL2 
breaks in two cases with available data. The patients were treated according to 
the protocols for BL and did not suffer from a relapse. 
figure 3 | Two lymphomas diagnosed as BL by means of morphology, immunopheno-
type and genetics that were classified as intermediates by gene expression profiling. A 
corresponds to case 5 in table 1, B corresponds to case 16 in table 1. All stainings are 
hematoxylin and eosin. 
BCl2 expression in pediatric conventionally diagnosed Bl is not 
associated with unfavorable outcome
In DLBCL co-expression of BCL2 and MYC is associated with poorer outcome. 
In our cohort of 13 mBL based on gene expression profiles and available clinical 
data the outcome is excellent and none of the patients for whom a molecular di-
agnosis was available in the current study showed a relapse (table 1). We thus 
analyzed a larger number of conventionally diagnosed BL treated according to 
protocols of the NHL-BFM study group. Forty three patients, for whom the BCL2 
expression status based on whole tissue section staining was available (including 
three patients that were analyzed by gene expression profiling), were registered in 
the NHL-BFM database, thus providing us with complete clinical data. Seventeen 
of 43 cases of conventionally diagnosed BL (39%)  were reported to show BCL2 
expression. There was no major difference in clinical variables between the group 
with and the group without known BCL2 expression status, with the exception that 
a lower number of cases with known BCL2-expression status had bone marrow 
involvement and elevated lactate dehydrogenase (LDH) levels (supplementary 
table 1). A comparison of the clinical variables, gender, age, stage, bone marrow 
involvement, central nervous system involvement, LDH, B-symptoms, risk groups 
and event-free survival, did not reveal any difference between 26 BCL2-negative 
and 17 BCL2-positive cases of conventionally diagnosed BL (table 2). 
table 2 | Patient characteristics of BCL2 positive and BCL2 negative patients suffering 
form BL followed by the NHL-BFM study group.
Characteristics Bcl2 neg (n=26) Bcl2 pos (n=17) P value 
(Chi)
Gender male 24 92% 15 88%
female 2 8% 2 12% 1.00
Age < 10 13 50% 9 53%
10-14 9 35% 3 18%
> 14 4 15% 5 29% 0.39
Stage of disease I 1 5% 0 0%
II 5 24% 5 33%
III 12 57% 8 53%
IV 1 5% 0 0%
B-AL 2 10% 2 13%
n.a. 0 0% - - 0.96
BM involvement yes 2 8% 2 12% 1.00
CNS involvement yes 2 8% 1 6% 1.00
LDH < 500 U/l 15 63% 10 59%
500-1000 U/l 6 25% 3 18%
> 1000 U/l 3 13% 4 24% 0.74
B symptoms yes 8 31% 3 18% 0.48
Risk group R1 0 0% 0 0%
R2 13 62% 9 60%
R3 3 14% 2 13%
R4 5 24% 4 27% 1.00
EFS 96+4% 82+9% 0.15 LR
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DisCussion
BCL2 is a member of the BCL2 family of proteins, which are involved in a variety 
of cellular processes and predominantly act in an anti-apoptotic manner (Siddiqui 
et al, 2015). BCL2 is a promising therapeutic target in lymphomas that express 
the protein (Johnson-Farley et al, 2015). In this study we show that BCL2 is ex-
pressed in a considerable number of conventionally diagnosed BL cases. The 
percentage of BCL2-positive conventionally diagnosed BL cases in the NHL-BFM 
database (39%) was higher than the percentage of conventionally diagnosed BL 
reported as positive in our tissue microarray study (23%). The difference might 
be due to the fact that full slides were analyzed for BCL2 expression for the NHL-
BFM data, which allows areas of local BCL2 reactivity to be detected that might 
escape identification using a TMA. Translocations involving BCL2 as a cause of 
BCL2 expression were ruled out in our study, confirming previous data (Hummel 
et al, 2006;Dave et al, 2006;Klapper et al, 2008). Whether other genetic aber-
rations, such as mutations in the promoter region or epigenetic mechanisms in 
BCL2-positive subclones of conventionally diagnosed BL, cause the protein’s ex-
pression has not yet been elucidated. It is worth mentioning that the widely used 
antibody clone 100/D5 (DAKO, Glostrup, Denmark) is sufficiently sensitive to 
identify BCL2 expression in conventionally diagnosed BL. In contrast to follicular 
lymphoma (Adam et al, 2013), mutations of BCL2 epitopes do not seem to influ-
ence immunoreactivity despite the fact that mutations in BCL2 occasionally occur 
in conventionally diagnosed BL (Love et al, 2012). It is important to mention, that 
BCL2 staining suffers from a high interobserver variability (de Jong et al, 2007).
In DLBCL the expression of BCL2 is associated with poorer survival, especially if 
co-expressed with MYC protein (Perry et al, 2014;Horn et al, 2013). Since all BL 
express high levels of MYC (Hummel et al, 2006;Dave et al, 2006), the BCL2-posi-
tive BL are MYC and BCL2 co-expressors. Our findings show that in conventionally 
diagnosed BL or mBL a co-expression of MYC and BCL2 is not associated with a 
poorer outcome. Certainly, the differences in therapeutic protocols might explain 
the different prognostic impact of MYC-BCL2 co-expression. All conventionally di-
agnosed BL and mBL cases in our study were pediatric patients who received 
intensive chemotherapy according to pediatric protocols. The DLBCL for which the 
negative prognostic impact of MYC-BCL2 co-expression has been demonstrated 
were mainly treated with less aggressive immunochemotherapy using a CHOP 
(cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, prednisolone) 
based regimen (Zhou et al, 2014). Whether intensified chemotherapy might over-
come the negative prognostic impact of MYC-BCL2 co-expression in DLBCL is 
still uncertain. It is worthy of note that a recent study of a young, high-risk cohort 
of DLBCL treated with intensified immunochemotherapy identified biological risk 
factors that differ from cohorts of elderly patients with DLBCL (Horn et al, 2015). 
Using our recently developed gene expression based classifier (Masque-Soler 
et al, 2013), we were able to apply nanostring technology to manually dissected 
areas of the lymphoma. BCL2-positive and BCL2-negative areas of the same 
lymphomas were independently and consistently classified as mBL, implying that 
the expression of BCL2 does not indicate a “transformation” of BL towards an in-
termediate lymphoma. To our knowledge, this is the first example of gene expres-
sion-based molecular diagnosis in independently analyzed areas of a lymphoma. 
The consistency of the results confirms the reliability of our multiplex assay and 
suggests that the molecular diagnosis based on our classifier is not influenced by 
intratumoral heterogeneity. 
We have previously shown that m-intermediates in children do not harbor a genetic 
“double hit” constellation and show more “Burkitt-ness” than adult m-intermediates 
(Klapper et al, 2008;Salaverria & Siebert, 2011). This suggests that the majority of 
m-intermediates in children and young adults are in fact BL, which escape the clas-
sification as mBL due to minor divergence of gene expression or simply the choice 
of the statistical cut-off in the current algorithms (Klapper et al, 2008). This study 
again identifies four m-intermediates among 17 lymphomas that were classified as 
conventionally diagnosed BL on the basis of morphology and immunophenotype. 
However, the clinical, pathological and genetic features of the m-intermediates, 
such as age, localization, site of the lymphoma, morphology, immunophenotype, 
cytogenetics and outcome, do not differ from mBL in this cohort of children and 
young adults. This finding raises questions as to the potential advantage of mo-
lecular over conventional diagnosis for mature aggressive B-cell lymphomas in 
children and adolescents. Obviously, m-intermediates in young patients do not 
present a clinically or biologically relevant subgroup. Since our cohort of molec-
ularly classified lymphomas is rather small, molecular diagnosis based on gene 
expression profiling needs to be evaluated in larger cohorts of lymphomas in chil-
dren and young adults to understand its value as a diagnostic and prognostic tool. 
Our data suggest that BCL2 expression is a feature detected to a variable extent 
in a considerable number of cases of BL. It is important to mention, that even 
a high expression intensity or a high number of BCL2 positive lymphoma cells 
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does not preclude the diagnosis of BL if all other features are compatible with this 
diagnosis, especially if BCL2 translocations are absent. BCL2 expression in a 
lymphoma that clinically, morphologically, immunophenotypically and genetically 
resembles BL is not sufficient to diagnose an intermediate lymphoma, especially 
if the BCL2 expression is developed only in a subgroup of lymphoma cells (as 
was the case in most of the specimens analyzed in this study).  
In summary, more than 20% of lymphomas with the clinical, morphological, im-
munophenotypical and genetic features of conventionally diagnosed BL express 
BCL2. This expression is variable in extent and can occur diffusely or be restrict-
ed to certain areas of the lymphoma. BCL2 expression in conventionally diag-
nosed BL is almost always weaker than in non-neoplastic T-cells. Molecular diag-
nosis of BCL2-positive conventionally diagnosed BL confirms the diagnosis in the 
vast majority of cases. The clinical significance of m-intermediates in children is 
uncertain at the current time. BCL2 expression in conventionally diagnosed BL is 
not associated with poorer outcome in pediatric patients. Diagnostic pathologists 
must be aware of the BCL2 expression pattern in conventionally diagnosed BL. 
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